中国组织工程研究 ›› 2016, Vol. 20 ›› Issue (14): 2073-2079.doi: 10.3969/j.issn.2095-4344.2016.14.014

• 干细胞移植 stem cell transplantation • 上一篇    下一篇

骨髓间充质干细胞移植对大鼠胃癌前病变模型的修复作用

刘洪锋1,李 潞2   

  1. 1南阳医学高等专科学校第一附属医院,河南省南阳市  473000;2郑州大学第二附属医院,河南省郑州市  450014
  • 收稿日期:2016-02-14 出版日期:2016-04-01 发布日期:2016-04-01
  • 作者简介:刘洪锋,男,1975年生,河南省方城县人,汉族,硕士,主治医师,主要从事普外科方面的研究。
  • 基金资助:

    河南省科技厅基础科技攻关课题(122300450037)

Bone marrow mesenchymal stem cell transplantation for gastric precancerous lesions in a rat model

Liu Hong-feng1, Li Lu2   

  1. 1First Affiliated Hospital of Nanyang Medical College, Nanyang 473000, Henan Province, China; 2Second Affiliated Hospital of Zhengzhou University, Zhengzhou 450014, Henan Province, China
  • Received:2016-02-14 Online:2016-04-01 Published:2016-04-01
  • About author:Liu Hong-feng, Master, Attending physician, First Affiliated Hospital of Nanyang Medical College, Nanyang 473000, Henan Province, China
  • Supported by:

    Precancerous Conditions; Gastric Mucosa; Bone Marrow; Mesenchymal Stem Cell Transplantation; Vascular Endothelial Growth Factors; Tissue Engineering

摘要:

文章快速阅读:

 

文题释义:
胃癌前病变:指一类容易发生癌变的胃黏膜病理组织学变化,即胃黏膜的异型增生和肠上皮化生,主要伴存于慢性萎缩性胃炎。胃癌的癌前状态包括肠化和不典型增生,肠化指胃黏膜被肠型黏膜所代替。肠化有小肠型和大肠型。大肠型又称不完全肠化,推测其酶系统不健全而使被吸收的致癌物质在局部累积,导致细胞的不典型增生可发生突变成癌。
血管内皮生长因子:也称血管通透性因子或促血管素,最初是在多种培养的肿瘤细胞系中发现的一种新型的生长因子,它能增加微血管与小静脉血管的通透性。后来发现,该因子特异性地作用于血管内皮细胞,并促进血管内皮细胞的增殖,所以定名为血管内皮生长因子。
 
背景:胃癌前病变是多种因素共同参与的长期发展过程,骨髓间充质干细胞有修复组织损伤的作用。
目的:探讨骨髓间充质干细胞移植对大鼠胃癌前病变的影响。
方法:将36只Wistar大鼠随机分为对照组、模型组和移植组。模型组和移植组建立大鼠胃癌前病变模型,移植组大鼠经尾静脉注射1 mL CM-dil标记的骨髓间充质干细胞(3 ×106个细胞),每周注射1次,一共3次,模型组和对照组同样方法经尾静脉注入等量的生理盐水。末次注射后1周处死大鼠,观察大鼠胃组织病理变化,检测胃黏膜中血管内皮生长因子的表达以及血清中细胞因子含量。
结果与结论:①移植组大鼠胃黏膜损伤较模型组轻,移植组血管内皮生长因子表达明显高于模型组和对照组(P < 0.05);②模型组和移植组血清白细胞介素17和γ-干扰素水平高于对照组(P < 0.05),移植组血清白细胞介素17和γ-干扰素水平低于模型组(P < 0.05);③结果表明,骨髓间充质干细胞通过增加胃黏膜病变部位血管内皮生长因子的表达,降低血清白细胞介素17和γ-干扰素水平,从而提高血管通透性,减轻炎症反应,阻断或者缓解癌前病变的发生。

中国组织工程研究杂志出版内容重点:干细胞;骨髓干细胞;造血干细胞;脂肪干细胞;肿瘤干细胞;胚胎干细胞;脐带脐血干细胞;干细胞诱导;干细胞分化;组织工程
ORCID: 0000-0002-5298-9207(刘洪锋)

关键词: 干细胞, 移植, 胃癌前病变, 骨髓间充质干细胞, 细胞移植, 细胞因子, 血管内皮生长因子

Abstract:

BACKGROUND: Precancerous lesions are a long-term development process in which many factors are involved. Bone marrow mesenchymal stem cells can repair tissue injury.

OBJECTIVE: To investigate the effect of bone marrow mesenchymal stem cell transplantation on gastric precancerous lesions in the rats.
METHODS: Thirty-six Wistar rats were randomly divided into control group, model group and transplantation group. Animal models of gastric precancerous lesions were established in the model and transplantation groups. Rats in the transplantation group were given 1 mL of CM-dil-labeled bone marrow mesenchymal stem cells (3×106 cells) via the tail vein, once a week, totally three times. Rats in the model and control group were subjected to the tail vein injection of the same volume of normal saline. Then, rats were sacrificed 1 week after final injection, and pathohistological changes in rat gastric tissue sections were observed. The expression of vascular endothelial growth factor in the gastric mucosa and levels of serum cytokines were detected.
RESULTS AND CONCLUSION: The severity of gastric mucosal injury in the transplantation group was lighter than that of the model group. The expression of vascular endothelial growth factor was significantly higher in the transplantation group compared with the model and control groups (P < 0.05). The levels of serum interleukin-17 and interferon-γ were significantly higher in the model group than the transplantation group followed by the control group (both P < 0.05). Therefore, bone marrow mesenchymal stem cells can increase vascular permeability, reduce inflammation, block or ease the occurrence of precancerous lesions by up-regulating the expression of vascular endothelial growth factor in the gastric mucosa lesions and reducing the expression of interleukin-17 and interferon-γ.
中国组织工程研究杂志出版内容重点:干细胞;骨髓干细胞;造血干细胞;脂肪干细胞;肿瘤干细胞;胚胎干细胞;脐带脐血干细胞;干细胞诱导;干细胞分化;组织工程

Key words: Precancerous Conditions, Gastric Mucosa, Bone Marrow, Mesenchymal Stem Cell Transplantation, Vascular Endothelial Growth Factors, Tissue Engineering